NEW YORK – (BUSINESS WIRE) – August 3, 2021–
PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that distinguished global industry leader Aster Angagaw has joined the Board of administration of its majority-owned subsidiary Lucid Diagnostics Inc.. (“Lucid”). Ms. Angagaw will serve on the Company’s audit and nominating committees.
This press release features multimedia. See the full version here: https://www.businesswire.com/news/home/20210803005717/en/
Global Industry Leader Aster Angagaw Joins Board of PAVmed Subsidiary Lucid Diagnostics (Photo: Business Wire)
“I am delighted to welcome Aster Angagaw to the Lucid Board of Directors,” said Lishan Aklog MD, President and CEO of PAVmed and Executive Chairman of Lucid. “She brings decades of business experience as a Managing Director, Global Transformation Leader and Public Company Director, with long, deep roots in the global healthcare industry. His experience working with large integrated healthcare delivery networks and knowledge of medical technology supply chain systems will be particularly valuable to our growing business operations. With Ms. Angagaw joining the newly appointed Stanley Lapidus and Dr. Jacque Sokolov, Lucid has a world-class Board of Directors with the diverse skills and experience to provide essential guidance as we seek to execute our ambitious long-term growth strategy.
“I have dedicated my career to mission-driven organizational transformation and strategic operational execution, largely while navigating the complexities of the healthcare industry,” said Ms. Angagaw. “I am very excited to join this innovative and growing medical technology company with a clear vision and a mission to save lives through widespread precancer screening using advanced technologies. I look forward to working with Dr. Aklog, the strong management team at Lucid and my esteemed colleagues on the Board of Directors. Together we have a unique opportunity to carry out this important mission.
Ms. Angagaw is currently a member of the board of directors of Owens & Minor Inc. (NYSE: OMI), a leading healthcare logistics company that provides vital supply chain services to healthcare providers. and manufacturers of health products, from disposable medical supplies to devices. and implants. She most recently served as President of ServiceMaster Brands, the $ 2.6 billion franchise services division of ServiceMaster Global Holdings Inc. (NYSE: SERV), a leading provider of essential services to residential customers and commercial. Last year, Ms. Angagaw guided the sale of the division to a private equity firm for $ 1.6 billion. Prior to ServiceMaster, she held a series of leadership roles at Sodexo SA (Euronext: SW), a Paris-based multinational diversified services company with 440,000 employees and sales of over $ 20 billion. Over 23 years at Sodexo, she has demonstrated great success in the areas of operations, strategy and business development, organizational transformation and customer loyalty. She became CEO, Healthcare North America, overseeing 6,000 employees providing services, facilities management and clinical technologies to top pediatric hospitals and oncology centers in the United States and Canada. Notable past roles at Sodexo included serving as a member of its Global Healthcare Executive Committee, Senior Vice President, Global Sales and Business Development Director, responsible for leading business development and building a unified global business organization for the global healthcare segment, and group vice president. President of Global Transformation, where she helped lead a transition of country-specific business units to a unified global model.
Ms. Angagaw has received numerous accolades and has been repeatedly named to Black Enterprise magazine’s list of the most influential black leaders in U.S. companies and most powerful women in business, as well as the list of the most influential women in America. American companies from Savoy magazine. She also received the Excellence in Leadership Award from the Diversity Leadership Council. In 2020, Aster received the 400 Distinguished 400 Years Award from the Commission on African American History.
She sits on the advisory board of Women in Business Collaborative, an alliance of business women organizations that work together to achieve equal position, pay and power for all women in business. She is also a member of the Executive Leadership Council, a national organization comprising current and former black CEOs and senior executives from Fortune 1000 and Global 500 companies, which has worked to create an inclusive corporate leadership pipeline and seeks to open channels of opportunities for development. black executives to have a positive impact on businesses and our communities.
Ms. Angagaw holds a BA in Organizational Management from Eastern University in Pennsylvania and an MBA from the Fox School of Business at Temple University. She is also a graduate of the Advanced Management Program at Harvard Business School.
About PAVmed and Lucid
PAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical technology company with a diverse product portfolio addressing unmet clinical needs encompassing a wide range of clinical areas with attractive regulatory pathways and market opportunities. Its principal subsidiary, Lucid Diagnostics Inc., markets the first and only commercial tools for the widespread early detection of esophageal cancer and precancer – the EsoGuard ® Esophageal DNA Test and the EsoCheck ® Esophageal Cell Collection Device. . Its GI Health division also includes the complementary esophageal ablation device EsoCure ™ with Caldus ™ technology. Another major subsidiary, Veris Health Inc., is a digital health company developing the first smart implantable vascular access port with biological sensors and wireless communication to improve personalized cancer care through remote patient monitoring. . Its Minimally Invasive Interventions division markets its CarpX ® minimally invasive device for carpal tunnel syndrome. Other divisions include Infusion Therapy (PortIO ™ implantable intraosseous vascular access device and NextFlo ™ intravenous infusion kit) and Emerging Innovations (non-invasive laser blood glucose monitoring, pediatric ear tubes and mechanical circulatory support). For more information, please visit www.pavmed.com, Follow us on Twitter, connect with us on LinkedIn, and watch our videos on Youtube. For more information on our majority owned subsidiary, Lucid Diagnostics Inc., please visit www.luciddx.com, follow Lucid on Twitter, and connect with Lucid on LinkedIn. For detailed information on EsoGuard, please visit www.EsoGuard.com and follow us on Twitter, Facebook and Instagram.
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. These forward-looking statements, based on the current beliefs and expectations of PAVmed’s management, are subject to risks and uncertainties, which could cause actual results to differ from forward-looking statements. The risks and uncertainties that may cause such differences include, among others, the volatility of the price of PAVmed common shares, Series W warrants and Series Z warrants; general economic and market conditions; uncertainties inherent in research and development, including the cost and time required to advance PAVmed’s products to regulatory submission; whether regulatory authorities will be satisfied with the design and results of the preclinical studies of PAVmed; if and when PAVmed’s products are authorized by regulatory authorities; market acceptance of PAVmed products once authorized and marketed; our ability to raise additional funds and other competitive developments. PAVmed has not yet received clearance from the FDA or other regulatory body to market many of its products. The Company is monitoring the COVID-19 pandemic and its impact on our business. The Company expects the significance of the COVID-19 pandemic, including the extent of its effects on the Company’s financial and operating results, to be dictated, among other things, by the success of efforts to contain it and the impact of the measures taken in response. New risks and uncertainties can arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond the control of PAVmed. For a more detailed list and description of these and other risks and uncertainties that may affect PAVmed’s future operations, see Part I, Article IA, “Risk Factors”, in the most recent PAVmed Annual Report. on Form 10-K filed with the Securities and Exchange Commission, as it may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by PAVmed after its report most recent annual. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in the events, conditions or circumstances on which such expectations may be based, or which may affect the likelihood that actual results differ from those contained in forward-looking statements.
View source version on businesswire.com:https://www.businesswire.com/news/home/20210803005717/en/
Director of Investor Relations
[email protected] Media
Katie Gallagher / Kristi Bruno
(617) 792-3937 / (617) 865-3940
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK
INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH HEALTH MEDICAL DEVICES
SOURCE: PAVmed Inc.
Copyright Business Wire 2021.
PUB: 03/08/2021 9:30 a.m. / DISC: 03/08/2021 9:32 a.m.